Figure 1.

Schematic depicting regulatory T cell (Treg) gene engineering. Resting Treg (CD45RA⁺FOXP3⁺) are activated with anti-CD3 and anti-CD28 antibodies to transduce cells with retro- and lentiviral vectors encoding T cell receptors (TCRs) or chimeric antigen receptors (CARs). These engineered Treg have a defined specificity and an activated effector phenotype (HLA-DR⁺ICOS⁺CTLA-4^hiCD25^hiFOXP3^hi) with potent suppressive potential.